



Research Article

CLARITHROMYCIN MUCOADHESIVE MICROSPHERES FOR ANTI- *HELICOBACTER PYLORI* THERAPY: FORMULATION AND *INVITRO* EVALUATION

N.VENKATESWARAMURTHY*, R. SAMBATHKUMAR, M.VIJAYABASKARAN AND P. PERUMAL

Department of Pharmaceutics, J.K.K.Nataraja College of Pharmacy, Komarapalayam-638183, India, Email : murthyvenki@rediffmail.com

Received 08 Jan 2010, Revised and Accepted 05 Feb 2010

ABSTRACT

Helicobacter pylori (*H.pylori*) is a gram-negative bacillus responsible for one of the most common infections found in humans worldwide. *H. pylori* causes gastric diseases, such as peptic ulcer, gastric mucosa associated lymphoma. Recent studies shows that, decreasing efficacy of therapies worldwide. One reason for the incomplete eradication of *H. pylori* is probably due to the short residence time of antimicrobial agents in the stomach so that effective antimicrobial concentration cannot be achieved in the gastric mucous layer or epithelial cell surfaces where *H. pylori* exists. The purpose of this study was to design mucoadhesive microspheres containing Clarithromycin as an anti-*H. pylori* agent to deliver the drug specifically to mucus layer where *H.pylori* resides and evaluate the effectiveness of the mucoadhesive microspheres for *H. pylori* eradication therapy. Microspheres were prepared by using Eudragit RL100 as matrix and Carbopol 974P as a mucoadhesive polymer. The microspheres were prepared by emulsion solvent evaporation technique. The prepared microspheres were evaluated with respect to the particle size, production yield, encapsulation efficiency, shape and surface properties, mucoadhesive property, *in vitro* drug release and suitability for anti *Helicobacter pylori* effect. The preliminary results show great promise for this delivery strategy in the treatment of *H. Pylori* infection.

Key words: *Helicobacter pylori*, Mucoadhesive, Microspheres.

INTRODUCTION

The discovery of *Helicobacter pylori* (*H. pylori*) offered the etiologic agent of the initiating event of the inflammatory cascade^{1,2}. It has been confirmed that the development of gastric cancer spans over several decades sequentially starting with the acquisition of *H. pylori* infection and the development of chronic active gastritis^{3,4}. Over time, the development of glandular atrophy and intestinal metaplasia takes place in a subset of patients. Finally, gastric cancer would eventually arise⁵. It was suggested that *H. pylori* infection leads to an increased risk, in the order of 4 to 9 folds, of developing precancerous gastric conditions especially when the infection occurs in childhood⁶⁻⁹. In 1994 the International Agency for Research on Cancer (IARC) monograph committee classified *H. pylori* as a class I carcinogen to Humans¹⁰. On the other hand, *H. pylori* are also the cause of other gastric diseases, such as peptic ulcer, gastric mucosa associated lymphoma¹³⁻¹⁵.

Clarithromycin has highest rate of eradication of *H. pylori* in monotherapy *in vivo*,¹⁶ However, some other reports and clinical trials indicate that the therapies cannot bring out complete eradication of *H. pylori* and suggest that the therapeutic effect needs more investigation^{17,18}. One reason for the incomplete eradication of *H. pylori* is probably due to the short residence time of antimicrobial agents in the stomach so that effective antimicrobial concentration cannot be achieved in the gastric mucous layer or epithelial cell surfaces where *H. pylori* exists^{19,20}. Mucoadhesive microspheres highly suitable drug delivery system for *H.pylori* eradication because it specifically bind with mucus where *H.pylori* resides and deliver the antibiotic for longer period. The purpose of this study was to

design mucoadhesive microspheres containing Clarithromycin as an anti-*H. pylori* agent and to evaluate the effectiveness of the mucoadhesive microspheres for *H. pylori* eradication therapy.

MATERIALS AND METHODS

Materials

Clarithromycin was gifted by Ranbaxy laboratories Ltd, New Delhi, India, was obtained as gifts from Colorcon Asia Pvt. Ltd., Mumbai, India and Carbopol 974P was a gift from BF Goodrich Co., Germany. Eudragit RL 100 was a gift sample from Microlabs, Bangalore. All other reagents and chemicals used were of analytical grade.

Preparation of Microspheres

Microspheres were prepared by a solvent evaporation method. The solvent system acetone/liquid paraffin was used. Agglomeration of microspheres was prevented by using 1% w/v Span80. Eudragit RL 100 was used to form a matrix of microspheres and mucoadhesive polymer were chosen to produce mucoadhesion is Carbopol 974P. Eudragit RL 100 was dissolved in acetone and weighed quantity of Clarithromycin, Carbopol 974P were dispersed in it. The total volume of acetone was 12 ml. This homogeneous final dispersion was cooled to 5 °C and poured slowly with stirring (700 rpm) into 80 ml of liquid paraffin containing 1% w/v span 80, which was previously also cooled to 5 °C. The obtained emulsion was stirred at 40 °C for 40 min. The suspension of microspheres in liquid paraffin was filtered and microspheres were washed by n-hexane and dried in vacuum at room temperature overnight.

Table 1: Formulation composition of mucoadhesive microspheres of Clarithromycin

Formulation Code	Ethyl cellulose 100(%w/v)	Carbopol 974P(%w/v)
F1	3	1.0
F2	5	1.0
F3	7	1.0
F4	5	0.5
F5	5	1.5
F6	5	2.0

Scanning electron microscopy

Scanning electron photomicrograph of Clarithromycin loaded mucoadhesive microspheres were taken. A small amount of microspheres was spread on glass stub. Afterwards, the stub containing the sample was placed in the scanning electron microscope (JSM 5610 LV SEM, JEOL, Datum Ltd, Tokyo, Japan) chamber. Scanning electron photomicrograph was taken at the acceleration voltage of 20 KV, chamber pressure of 0.6 mm Hg, at different magnification.

Particle size measurement

The prepared microspheres were sized by using a Malvern 2600 Laser Diffraction Spectrometer. The size of the microspheres was determined in n-hexane as a non-dissolving dispersion medium and the particles were suspended mechanically by magnetic stirring during the measurement.

Degradation of clarithromycin in pH 1.2²¹

The degradation rate of the antimicrobial agent at pH 1.2 was examined by reported method with slight modification. A known amount of clarithromycin was added to the medium, which was preheated at 37°C±0.2°C, to make a final concentration of 10.0 µg/ml. An aliquot of the medium was withdrawn at predetermined

time intervals and neutralized with a NaOH solution before being quantified by HPLC. Then the solution was filtrated through a 0.45 µm syringe filter then analyzed for clarithromycin content by reversed-phase high performance liquid chromatography (RPHPLC) method using a mobile phase consisting of acetonitrile-aqueous 0.05 M phosphate buffer solution of pH 4.0 (40:60 v/v). The apparatus used for HPLC analysis was an Agilent 1100 quaternary pump, with a variable wavelength detector, thermostatted autosampler and column thermostat. A Hypersil ODS C18 column (250mm×4.6mm ID, 5 µm, Thermo, UK) was fitted with a Phenomenex guard column packed with octadecyl C18 (Phenomenex, USA). The column temperature was maintained at 40°C and flow rate of 1ml/min. The concentrations of the parent drug remaining were analyzed by RP-HPLC assay. The degradation of clarithromycin was assumed to follow pseudo-first order kinetics, which is described by the following equation:

$$C=C_0e^{-kt}$$

in which *C* is the concentration of clarithromycin remaining at time *t*, *C*₀ is the initial concentration of clarithromycin, and *k* is the pseudo-first order degradation rate constant. The half-life (*t*_{1/2}) of clarithromycin was determined from the pseudo-first order degradation rate constant. Degradation rate constant used to correct the drug release data obtained in acidic media.




Fig. 1: SEM photograph of microsphere (Formulation F6)

Table 2: Physico-chemical characteristics of the Clarithromycin loaded mucoadhesive microspheres

S.No	Formulation code	Mean Particle size (µm)	Drug Entrapment (%) ±S.D (n=3)	Mucoadhesion (%) ±S.D* (n=3)
1	F1	155	82± 1.71	83±0.153
2	F2	273	88±1.32	85±1.134
3	F3	311	90±1.51	88±1.09
4	F4	173	90±1.67	83±1.756
5	F5	251	86±1.54	92±1.987
6	F6	306	82±1.13	95±1.644

S.D = Standard deviation

Determination of drug encapsulation efficiency

To determine the total drug content of microspheres a known amount of microspheres were ground to fine powder. Accurately weighed (50mg) grounded powder of microspheres were soaked in 50 ml of distilled water and sonicated using probe sonicator for 2 h. The whole solution was centrifuged using a tabletop centrifuge to remove the polymeric debris. Then the polymeric debris was washed twice with fresh solvent (water) to extract any adhered

drug. The clear supernatant solution was filtrated through a 0.45 µm syringe filter then analyzed for Clarithromycin content by high performance liquid chromatography and the conditions for the HPLC assay were the same as before.

In Vitro Drug Release Studies

Release of Clarithromycin from the microspheres was studied in 0.1N HCL (900 mL) using a USP XXIII paddle method Dissolution Rate Test Apparatus (Dissco 2000, Labindia) with a rotating

paddle stirrer at 50 rpm and $37 \pm 1^\circ\text{C}$. A sample of microspheres equivalent to 25 mg of Clarithromycin was used in each test. Samples of dissolution fluid were withdrawn through a filter ($0.45 \mu\text{m}$) at different time intervals and were assayed for drug release by high performance.

In vitro evaluation of mucoadhesiveness²²


A strip of goat intestinal mucosa was mounted on a glass slide and accurately weighed mucoadhesive microspheres in dispersion form was placed on the mucosa of the intestine. This glass slide was incubated for 15 min in a desiccator at 90% relative humidity to allow the polymer to interact with the membrane and finally placed in the cell that was attached to the outer assembly at an angle 45° . Phosphate buffer saline (pH 6.4), previously warmed to $37 \pm 0.5^\circ\text{C}$,

was circulated to the cell over the microspheres and membrane at the rate of 1 ml/min with the help of pump. Washings were collected at different time intervals and microspheres were separated by centrifugation followed by drying at 50°C . The weight of microspheres washed out was taken and percentage mucoadhesion was calculated by

$$\text{Percentage mucoadhesion} = \frac{W_a - W_l \times 100}{W_a}$$

where W_a = weight of microspheres applied; W_l = weight of microspheres leached out.

liquid chromatography. The drug release experiments were conducted in triplicate ($n = 3$).



RESULTS AND DISCUSSION

The mucoadhesive microspheres Clarithromycin prepared in this study were well-rounded spheres with the size ranging approximately from 155 to $306 \mu\text{m}$. The study of in vitro bioadhesion revealed that all the batches of prepared microspheres had good bioadhesive property ranging from $83 \pm 0.153\%$ to $95 \pm 1.644\%$. From the result of the in vitro release test, the effect of Eudragit RL100 concentration on Clarithromycin release from were observed a significant decrease in the rate and extent of drug release was observed with the increase in polymer concentration in microspheres and could be attributed to increase in the density of the polymer matrix and also increase in the diffusional path length which the drug molecules have to traverse. Similarly, the effect carbopol 974p concentration on release properties of Clarithromycin were also studied. An increase in carbopol 974p concentration caused retardation in drug release from the microspheres because of an increase in the viscosity of polymer solution and formation larger size microspheres. In vitro studies clearly indicates that the prepared formulations possess good bioadhesive properties. These properties enable the microspheres to adhere to the gastric mucosal surface and stay in stomach for prolonged periods and could ensure the stability of Clarithromycin in gastric environment, which eventually resulted in better eradication of *H. pylori* than the conventional dosage forms.

REFERENCES

- Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. *CA Cancer J Clin* 2001; 51: 15-36.
- Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988; 48: 3554-60.

- Siurala M, Sipponen P, Kekki M. Chronic gastritis: Dynamic and clinical aspects. *Scand J Gastroenterol Suppl* 1985; 109: 69-76.
- Rozen P. Cancer of the gastrointestinal tract: Early detection or early prevention? *Eur J Cancer Prev* 2004; 13: 71-75.
- Israel DA, Peek RM. Pathogenesis of Helicobacter pylori-induced gastric inflammation. *Aliment Pharmacol Ther* 2001; 15: 1271-90.
- Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N et al, Association between infection with Helicobacter pylori and risk of gastric cancer: Evidence from a prospective investigation. *BMJ* 1991; 302: 1302-5.
- Camargo MC, Yopez MC, Ceron C, Guerrero N, Bravo LE, Correa P et al, Age at acquisition of Helicobacter pylori infection: Comparison of two areas with contrasting risk of gastric cancer. *Helicobacter* 2004; 9: 262-70.
- Correa P. The biological model of gastric carcinogenesis. *IARC Sci Publ* 2004; 157: 301-9.
- TU, Haapiainen R, Puolakkainen P. The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia. *Aliment Pharmacol Ther* 2002; 16: 515-20.
- Testino G. Gastric preneoplastic changes. *Recenti Prog Med* 2004; 95: 239-44.
- Caruso ML, Fucci L. Histological identification of Helicobacter pylori in early and advanced gastric cancer. *J Clin Gastroenterol* 1990; 12: 601-2.
- Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney system. International Workshop on the Histopathology of gastritis, Houston 1994. *Am J Surg Pathol* 1996; 20: 1161-81.
- Ozasa K, Kurata JH, Higashi A, Hayashi K, Inokuchi H, Miki K et al. Helicobacter pylori infection and atrophic gastritis: A nested case-control study in a rural town in Japan. *Dig Dis Sci* 1999; 44: 253-6.

14. Uemura N. The trend of the research on H pylori eradication and gastric cancer prevention. *Nippon Rinsho* 2004; 62: 571-6.
15. Asaka M, Kato M, Kudo M, Katagiri M, Nishikawa K, Yoshida J et al. Relationship between Helicobacter pylori infection, atrophic gastritis and gastric carcinoma in a Japanese population. *Eur J Gastroenterol Hepatol* 1995; 7(Suppl):S7-S10.
16. K.C. Myung, S. Hongkee, C. Hoo-Kyun, Preparation of mucoadhesive microspheres containing antimicrobial agents for eradication of H. pylori, *Int J Pharm* 2005;297:172-9.
17. Lin CK, Hsu PI, Lai KH. One-week quadruple therapy is an effective salvage regimen for Helicobacter pylori infection in patients after failure of standard triple therapy. *J Gastroenterol* 2002;34:547-51.
18. Kawabami E, Ogata SK, Portorreal AC. Triple therapy with clarithromycin, amoxicillin and omeprazole for Helicobacter pylori eradication in children and adolescents. *Arq Gastroenterol* 2001;38: 203-6.
19. Cooreman MP, Krausgrill P, Hengels KJ. Local gastric and serum amoxicillin concentrations after different oral application forms. *Antimicrob Agents Chemother* 1993;37:1506-9.
20. Atherton JC, Cockayne A, Balsitis M, Kirk GE, Hawley CJ, Spiller RC. Detection of the intragastric sites at which Helicobacter pylori evades treatment with amoxicillin and cimetidine. *Gut* 1995;36:670-4.
21. Zhepeng L., Weiyue L, Lisheng Q, Xuhui Z, Pengyun Z, Jun P, In vitro and in vivo studies on mucoadhesive microspheres of amoxicillin. *J Control Rel* 2004;81:327-34.
22. Jain SK, Chourasia MK, Jain AK, Jain RK. Development and characterization of Mucoadhesive Microspheres Bearing Salbutamol for Nasal Delivery, *Drug Deliv* 2004;11: 113-22.